identifi ed using two databases. Th e hospital's reference laboratory (med fusion) was queried for positive results that included serum or CSF WNV IgM and IgG antibodies and WNV polymerase chain reaction (PCR) tests. Our laboratory used the IgM Capture DxSelect TM enzyme-linked immunosorbent assay and Focus Diagnostics IgG DxSelect TM enzyme-linked immunosorbent assay for qualitative detection of WNV IgM and IgG antibodies. Positive results were submitted to the Texas Department of State Health Services for confi rmatory testing. Tests for WNV PCR were submitted to ARUP Laboratories, which uses qualitative real-time PCR to test serum and CSF in accordance with Roche Molecular Systems methods (13) .
Th e institutional administrative coding database was crossreferenced for diagnoses of WNV infection. Patients with prior WNV disease or only WNV IgG antibodies whose clinical picture wasn't compatible with acute disease were excluded. Extracted data included demographics, comorbidities, symptoms, relevant physical examination fi ndings, admission location, complications, diagnostic test results, and disposition. Immunosuppression was considered if records documented another disease known to aff ect the immune system or immunosuppressive therapy with systemic steroids (prednisone >20 mg or equivalent steroid longer than 2 weeks), biologic agents, or other immunomodulatory drugs.
Cases were classifi ed as confi rmed WNF, probable WNF, confi rmed WNND, or probable WNND per case defi nition criteria of the Centers for Disease Control and Prevention (CDC) (14) . To address variable clinician evaluation and capture patients not fulfi lling CDC defi nitions whose composite clinical and laboratory data suggested WNF or WNND, categories of "possible" WNF and WNND were created. For example, some patients not meeting the defi nition of fever had laboratory evidence in serum or CSF supporting active WNV infection. Th e study was approved by the institutional review board of BUMC.
West Nile virus and the 2012 outbreak: The Baylor University Medical Center experience
RESULTS
Sixty-eight cases were identifi ed and 13 eliminated by our exclusion criteria. Fifty-fi ve cases were evaluated: 12 comprised the WNF group (7 probable, 5 possible, and none confi rmed), and 43 comprised the WNND group (7 confi rmed, 29 probable, and 7 possible). Patient characteristics and comorbidities are summarized in Table 1 . Th e age range was 19 to 84 years, with a mean of 53.4 years. Most patients were white, non-Hispanic men. Body mass index ranged from 15.7 to 62.4 kg/m 2 , with a mean of 28.8 kg/m 2 . Th e most common comorbid condition was hypertension.
Presenting complaints and fi ndings are outlined in Table 2 . Subjective fevers were reported by 52 patients (42 had a documented fever of >100.4°F), classifying 10 patients as "possible" WNV infection (5 WNF, 5 WNND). Other fi ndings were headache, altered mental status, hyponatremia, and gastroenteritis. Less common were seizures, acute kidney injury, acute respiratory failure, elevated transaminases, elevated total bilirubin, acute fl accid paralysis, rhabdomyolysis, tremors, myoclonus, and atrial fi brillation. In the WNND group, 26 had headache, 27 had altered mental status, 12 had seizures, and 3 had acute fl accid paralysis. Th e most commonly reported symptoms in the WNF group were headache and gastrointestinal symptoms. In this group, fever >100.4°F was documented in 7 patients and altered mental status was an uncommon presentation. Table 2 also outlines diagnostic laboratory fi ndings. Serum WNV IgM antibodies were positive in most patients. Two patients (both WNND) had detectable total WNV antibodies that weren't fractionated into IgM or IgG components, deeming them "possible" WNV infection. Serum PCR WNV was performed in one patient and was undetectable. Serum arbovirus panels were obtained in six patients and were negative.
In the WNND group, a serum WNV IgM test was positive in 35 patients, negative in 2, and not obtained in 6 (including the two with positive total unfractionated WNV antibody). Serum WNV PCR was not obtained in any WNND patient. However, all had clinical neurological fi ndings compatible with WNND, as defi ned by CDC clinical criteria (Table 3) . Fortythree patients underwent lumbar puncture. Cell counts were available on 42, and 37 had pleocytosis. In the WNND group, cell counts were available in 37, and 35 had pleocytosis. Th irtytwo patients had CSF analysis for WNV IgM, and 19 had detectable CSF WNV IgM antibodies. Th ree had a positive CSF WNV PCR, but the test was only ordered in 14. CSF WNV IgG antibody testing was performed in 8 of the 43 patients; only one patient tested positive.
Th irty-two patients (25 WNND) were initially admitted to a medicine fl oor; 19 (17 WNND) to the intensive care unit, and 4 (1 WNND) were seen and discharged in the emergency department. Th e mean length of stay for all was 7.7 days (WNND, 8.9 days; WNF, 3.2 days). In the WNF group, 11 were discharged home and one to a rehabilitation facility. In contrast, for WNND, 23 were discharged home, 7 to a rehabilitation unit, 2 to a long-term acute care facility, 2 to a skilled nursing facility, and 9 died. Th e mortality rate was 21%. Of all compromised. Several patients had multiple comorbidities. All presented with altered mental status and subjective fever (8 documented a fever of ≥100.4°F). Eight were admitted to the intensive care unit. Seven had acute respiratory failure requiring mechanical ventilation, and six had seizures.
DISCUSSION
Th is study highlights WNV outbreak challenges. One challenge was related to case classifi cation, given strict CDC criteria (14) . Twenty-two percent of patients didn't fulfi ll CDC case defi nitions for confi rmed or probable WNND or WNF (Table 3) . Th ey lacked a documented fever >100.4°F and/or specifi c confi rmatory testing. Elderly patients and those with renal failure or receiving corticosteroids may have had compromised febrile response mechanisms (15, 16 WNV deaths in the four-county area, 24% were hospitalized at BUMC. Among the 9 patients who died, 8 were older than 50 years of age; 6 were men, 4 were white, 3 were Hispanic, and 2 were black. Six had hypertension, 6 had diabetes mellitus, 5 had chronic or end-stage renal disease, and 3 were immuno- Rehabilitation facility 1 7
Long-term care facility 0 2
Skilled nursing facility 0 2 Death 0 9
Mortality rate (%) 0% 21%
Data analysis suggests opportunities to improve our response to outbreaks. Lessons learned include the need to 1) remain vigilant for the diagnosis of WNV; 2) educate staff in recognizing real-world manifestations of WNV infection, which doesn't neatly lend itself to published criteria for diagnosis; 3) develop standardized diagnostic testing algorithms; 4) develop recommendations for multisystem supportive care in WNF and WNND patients; and 5) research strategies for better detection, prevention, and treatment, including refi ned molecular tools for viral identifi cation. Plans are currently under way at BUMC to optimize response to future outbreaks. Some activities involve developing standardized testing protocols and guidelines for the care of patients with possible WNV infection. However, further studies are needed as we search for more eff ective diagnostic, supportive, and therapeutic measures.
acute illness or in immunosuppressed populations. Such testing can be costly, and with decreasing reimbursement, physicians may be reluctant to order molecular diagnostics when eff ective therapeutic options are lacking. Additionally, tests measuring neutralizing antibodies aren't widely available (limited to state departments of health and the CDC).
Physician unfamiliarity with the presentations of WNV illness, coupled with the lack of standardized testing protocols for suspected disease, contributed to uncertainty in the classifi cation of some cases. To avoid excluding potential cases, we employed a category of "possible" WNV infection as described previously. We suggest the CDC adopt a defi nition of "possible WNV infection" for reporting and potentially therapeutic purposes.
For case defi nition, arboviral testing should be limited to known regional endemic viruses. Th e presence of endemic viruses in sentinel populations could be utilized in CDC case defi nitions. In the absence of active endemic viruses in humans or sentinel populations, no further arboviral testing is necessary. For example, St. Louis encephalitis virus infections previously endemic to our area were not detected in humans, sentinel fl ocks, or mosquito pools during the 2012 season (17, 18). We suggest the CDC laboratory diagnostic criterion "negative arboviral serologies for endemic arboviruses" be revised to refl ect the absence of other endemic arboviruses in mosquitoes and sentinel birds in the aff ected geographic area during an epidemic.
Additional diffi culties involved distinguishing between true WNND and WNF with nonspecifi c neurologic symptoms. Determining whether WNV infection was a primary or contributory cause of death was problematic. Although most of the autopsied patients had CNS lesions that were clearly suffi cient to explain death, one patient did not have well-developed CNS pathology.
Th e literature cites evidence that systemic WNV infection may cause direct injury to organs, exacerbating preexisting diseases (19) (20) (21) . Th is may complicate the diagnostic evaluation when attempting to decipher what is or is not attributable to WNV infection. WNV may contribute to the death of patients with signifi cant underlying comorbidities in the absence of defi nitive CNS involvement. Data published by Schanzer et al reviewed the potential contributory role of infl uenza and found many comorbidities to be associated with infl uenza-attributed deaths, particularly pulmonary and cardiac diseases (21) . It is important to realize that WNV may have systemic implications. We caution that misidentifi cation of potentially treatable conditions could delay appropriate therapy.
Furthermore, historical data review found distribution differences in WNF and WNND cases in 2003 versus 2012 (22, 23) . In 2003, the WNF:WNND ratio was approximately 2.4:1; in 2012, this ratio was approximately 1:1. Both observations raise the possibility that the virus may have become more neurotropic due to viral mutation and genetic drift. Other possibilities include changes in testing patterns with improved detection related to patient and physician awareness and immunity of the population at risk. Of concern, despite increased awareness and prevention with DEET, mortality has not substantially decreased.
